Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

<p><strong>Purpose:</strong> Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is...

Full description

Bibliographic Details
Main Authors: Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG
Format: Journal article
Language:English
Published: American Society of Clinical Oncology 2023

Similar Items

Similar Items